Article List

WPRIM Management System> DCMS> Journal of Gynecologic Oncology> 2013> 24> 3

Volume: 24 Issue: 3

1. Selective cyclooxygenase inhibitors increase paclitaxel sensitivity in taxane-resistant ovarian cancer by suppressing P-glycoprotein expression.	Page:273—279
2. The course of fatigue in patients with gynecologic and breast cancer.	Page:280—286
3. Neoadjuvant chemotherapy followed by fertility-sparing surgery for women with stage IB1 cervical cancer.	Page:287—290
4. Thrombin promotes epithelial ovarian cancer cell invasion by inducing epithelial-mesenchymal transition.	Page:265—272
5. The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer.	Page:258—264
6. Ovarian cancer mortality among women aged 40-79 years in relation to reproductive factors and body mass index: latest evidence from the Japan Collaborative Cohort study.	Page:249—257
7. Prognostic factors associated with local recurrence in squamous cell carcinoma of the vulva.	Page:242—248
8. Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia.	Page:236—241
9. Prognostic factors and treatment outcome after radiotherapy in cervical cancer patients with isolated para-aortic lymph node metastases.	Page:229—235
10. Multivariate prognostic analysis of adenocarcinoma of the uterine cervix treated with radical hysterectomy and systematic lymphadenectomy.	Page:222—228
11. p16INK4a immunohistochemistry is a promising biomarker to predict the outcome of low grade cervical intraepithelial neoplasia: comparison study with HPV genotyping.	Page:215—221
12. Updates of the current screening guidelines for the early detection of cervical cancer.	Page:212—214
13. Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer.	Page:209—211